Acute Coronary Syndrome Clinical Trial
Official title:
A Prospective Study of the BioFreedom™ Biolimus A9™ Drug Coated Stent in Patients at High Risk for Bleeding
Verified date | February 2021 |
Source | Biosensors Europe SA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to confirm non-inferiority of the BioFreedom™ Drug Coated Stent to the Gazelle™ Bare Metal Stent arm of the Leaders Free study (NCT01623180) in high bleeding risk patients.
Status | Active, not recruiting |
Enrollment | 1203 |
Est. completion date | March 2021 |
Est. primary completion date | October 11, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: Any indication for percutaneous coronary intervention with stent placement (PCI-S) in patients deemed at high risk for bleeding and candidates for 1 month dual anti-platelet therapy (DAPT). This includes candidates with stable angina, silent ischemia, acute coronary syndrome (STEMI and non-STEMI), non-native lesions and in-stent restenosis. Patients must provide written informed consent. Reasons of unsuitability for > 1 month dual antiplatelet treatment must include one or more of the following: 1. Adjunctive oral anticoagulation treatment planned to continue after PCI 2. Age = 75 years old 3. Baseline Hgb <11 g/dl (or anemia requiring transfusion during the 4 weeks prior to the index procedure) 4. Any prior intracerebral bleed 5. Any stroke in the last 12 months 6. Hospital admission for bleeding during the prior 12 months 7. Non skin cancer diagnosed or treated < 3 years, with a perceived increased risk for bleeding 8. Planned daily Nonsteroidal anti-inflammatory drugs (NSAID) (other than aspirin) or steroids for >30 days after PCI 9. Planned surgery that would require interruption of DAPT (within next 6 months) 10. Renal failure defined as: Creatinine clearance <40 ml/min 11. Thrombocytopenia (PLT <100,000/mm3) 12. Severe chronic liver disease defined as: patients who have developed any of the following: variceal hemorrhage, ascites, hepatic encephalopathy or jaundice 13. Expected non-compliance to prolonged DAPT for other medical reasons Exclusion Criteria: 1. Pregnant and breastfeeding women 2. Patients expected not to comply with 1 month DAPT 3. Patients requiring a planned staged PCI procedure more than one week after the index procedure 4. Procedure planned to require non-study stents, or stand-alone plain old balloon angioplasty (POBA) or stand-alone atherectomy 5. Active bleeding at the time of inclusion 6. Reference vessel diameter <2.25 - >4.0mm 7. Cardiogenic shock 8. Compliance with long-term single anti-platelet therapy unlikely 9. A known hypersensitivity or contraindication to aspirin, clopidogrel (or prasugrel, or ticagrelor if applicable), stainless steel, zinc, Biolimus A9™ or a sensitivity to contrast media, which cannot be adequately pre-medicated 10. PCI during the previous 12 months for a lesion other than the target lesion of the index procedure 11. Participation in another clinical trial (12 months after index procedure) 12. Patients with a life expectancy of < 12 months 13. Patients under judicial protection, tutorship or curatorship (for France only) |
Country | Name | City | State |
---|---|---|---|
Canada | Mazankowski Alberta Heart Institute | Edmonton | Alberta |
Canada | Hamilton Health Sciences | Hamilton | Ontario |
Canada | Centre Hospitalier de l'université de Montréal | Montréal | Quebec |
Canada | Hôpital Maisonneuve-Rosemont | Montréal | Quebec |
Canada | Montreal Heart Institute | Montréal | Quebec |
Canada | Fraser Clinical Trials Inc. | New Westminster | British Columbia |
Canada | The University of Ottawa Heart Institute | Ottawa | Ontario |
Canada | Institut universitaire de cardiologie et de pneumologie de Québec | Québec | Quebec |
Canada | CIUSSS de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke | Sherbrooke | Quebec |
Canada | St. Paul's Hospital | Vancouver | British Columbia |
Canada | Victoria Heart Institute Foundation | Victoria | British Columbia |
Denmark | Rigshospitalet Copenhagen University Hospital | Copenhagen | |
France | Clinique Axium | Aix-en-Provence | |
France | Service de Cardiologie Interventionnelle - Pôle Santé République | Clermont-Ferrand | |
France | Clinique de Fontaine | Fontaine-lès-Dijon | |
France | Groupe Hospitalier Mutualiste de Grenoble | Grenoble | |
France | Hôpital Privé Jacques Cartier ICPS | Massy | |
France | Hôpital Privé Claude Galien | Quincy-sous-Sénart | |
France | Clinique Saint Hilaire | Rouen | |
France | CHU Toulouse Rangeuil | Toulouse | |
Germany | Segeberger Kliniken GmbH | Bad Segeberg | |
Germany | Herzzentrum Leipzig GmbH | Leipzig | |
Italy | Grande Ospedale Metropolitano Niguarda | Milan | |
Italy | Azienda Ospedaliera San Camillo Forlanini | Rome | |
United Kingdom | Royal Bournemouth Hospital, Dorset Heart Centre | Bournemouth | |
United Kingdom | Craigavon Cardiac Centre | Craigavon | |
United Kingdom | Golden Jubilee National Hospital | Glasgow | |
United States | AnMed Health | Anderson | South Carolina |
United States | McLaren Bay Region | Bay City | Michigan |
United States | St. Luke's Idaho Cardiology Associates | Boise | Idaho |
United States | University of Buffalo | Buffalo | New York |
United States | Lahey Clinic | Burlington | Massachusetts |
United States | Novant Health Heart and Vascular Institute | Charlotte | North Carolina |
United States | Chattanooga Heart Institute | Chattanooga | Tennessee |
United States | Jesse Brown VA Medical Center | Chicago | Illinois |
United States | Missouri Cardiovascular Specialists, LLP | Columbia | Missouri |
United States | North Georgia Heart Foundation | Gainesville | Georgia |
United States | LeBauer Cardiovascular Research Foundation | Greensboro | North Carolina |
United States | Penn State - Milton S. Hershey Medical Center | Hershey | Pennsylvania |
United States | Tri-Lakes Research | Hot Springs | Arkansas |
United States | Houston Methodist Hospital | Houston | Texas |
United States | Heart Center Research, LLC | Huntsville | Alabama |
United States | St. Vincent Heart Center | Indianapolis | Indiana |
United States | University of Florida Jacksonville | Jacksonville | Florida |
United States | Saint Luke's Hospital of Kansas City | Kansas City | Missouri |
United States | Tennova Healthcare-Turkey Creek Medical Center | Knoxville | Tennessee |
United States | Scripps Health | La Jolla | California |
United States | University of California San Diego | La Jolla | California |
United States | Jewish and St. Mary's Hospital | Louisville | Kentucky |
United States | MidMichigan Medical Center Midland | Midland | Michigan |
United States | Columbia University Medical Center/New York Presbyterian Hospital | New York | New York |
United States | Weill Cornell Medical College-New York Presbyterian | New York | New York |
United States | Penn Presbyterian Medical Center | Philadelphia | Pennsylvania |
United States | Rhode Island Hospital | Providence | Rhode Island |
United States | NC Heart and Vascular Research | Raleigh | North Carolina |
United States | Black Hills Cardiovascular Research | Rapid City | South Dakota |
United States | Berks Cardiologists, Ltd. | Reading | Pennsylvania |
United States | Carilion Clinic | Roanoke | Virginia |
United States | William Beaumont Hospital | Royal Oak | Michigan |
United States | Santa Barbara Cottage Hospital | Santa Barbara | California |
United States | Velella Research | Sarasota | Florida |
United States | Tallahassee Research Institute, Inc. | Tallahassee | Florida |
United States | Providence Health Center | Waco | Texas |
United States | MedStar Washington Hospital Center | Washington | District of Columbia |
United States | Pinnacle Health Cardiovascular Institute | Wormleysburg | Pennsylvania |
United States | Genesis Healthcare System | Zanesville | Ohio |
Lead Sponsor | Collaborator |
---|---|
Biosensors Europe SA |
United States, Canada, Denmark, France, Germany, Italy, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The composite of cardiac death and myocardial infarction at twelve months | 12 months | ||
Primary | The incidence of clinically driven target lesion revascularization at twelve months | 12 months | ||
Secondary | The composite of cardiac death and myocardial infarction | 1, 2, and 6 months and 2 and 3 years | ||
Secondary | The incidence of clinically driven target lesion revascularization | 1, 2, and 6 months and 2 and 3 years | ||
Secondary | The composite of cardiac death, myocardial infarction and stent thrombosis | 1, 2, and 6 months and 1, 2, and 3 years | ||
Secondary | Bleeding per Bleeding Academic Research Consortium (BARC) Criteria | 1, 2, and 6 months and 1, 2, and 3 years | ||
Secondary | Cardiac Death | 1, 2, and 6 months and 1, 2, and 3 years | ||
Secondary | Myocardial Infarction | 1, 2, and 6 months and 1, 2, and 3 years | ||
Secondary | Stent Thrombosis per Academic Research Consortium (ARC) Definition | 1, 2, and 6 months and 1, 2, and 3 years | ||
Secondary | Urgent target lesion revascularization | 1, 2, and 6 months and 1, 2, and 3 years | ||
Secondary | Clinically driven target lesion revascularization at time points other than primary endpoint | followed for all target lesion revascularizations, up to 3 years | ||
Secondary | Clinically driven target vessel revascularization | 1, 2, and 6 months and 1, 2, and 3 years | ||
Secondary | All cause mortality | 1, 2, and 6 months and 1, 2, and 3 years | ||
Secondary | Primary endpoints, in patients with at least 1 lesion treated with a trial stent of 3mm or less in nominal diameter | 1, 2, and 6 months and 1, 2, and 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT05412927 -
AngelMed Guardian® System PMA Post Approval Study
|
||
Completed |
NCT02750579 -
Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?
|
N/A | |
Completed |
NCT04102410 -
Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients
|
N/A | |
Enrolling by invitation |
NCT03342131 -
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome
|
N/A | |
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Enrolling by invitation |
NCT04676100 -
International CR Registry
|
||
Completed |
NCT03590535 -
5th Generation cTnT in ED ACS
|
||
Recruiting |
NCT05437900 -
INSIGHTFUL-FFR Clinical Trial
|
Phase 4 | |
Completed |
NCT05551429 -
Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
|
||
Terminated |
NCT04316481 -
IDE-ALERTS Continued Access Study
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT04852146 -
Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
|
||
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Completed |
NCT02944123 -
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
|
Phase 3 | |
Completed |
NCT04077229 -
Piloting Text Messages to Promote Positive Affect and Physical Activity
|
N/A | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Active, not recruiting |
NCT02922140 -
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
|
N/A | |
Completed |
NCT02673437 -
Rivaroxaban ACS Specialist Cohort Event Monitoring Study
|